Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has provided an announcement.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. has received approval from the National Medical Products Administration for a new indication of its Class 1 innovative drug, Ivarmacitinib Sulfate Tablets, for the treatment of severe alopecia areata in adults. This approval marks a significant advancement for the company, potentially enhancing its market position and offering new treatment options for patients suffering from this chronic condition.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a pharmaceutical company based in China, focusing on the development and production of innovative drugs. The company operates in the pharmaceutical industry and is known for its research and development of new medications, particularly in the field of oncology and other therapeutic areas.
Average Trading Volume: 6,461,033
Current Market Cap: HK$374.9B
For detailed information about 1276 stock, go to TipRanks’ Stock Analysis page.